Selected article for: "cov infect and host response"
Author: Yuan, Lunzhi; Tang, Qiyi; Zhu, Huachen; Guan, Yi; Cheng, Tong; Xia, Ningshao
Title: SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications
  • Cord-id: x95ccner
  • Document date: 2021_9_17
    • ID: x95ccner
    Snippet: SARS-CoV-2 has been the causative pathogen of the pandemic of COVID-19, resulting in catastrophic health issues globally. It is important to develop human-like animal models for investigating the mechanisms that SARS-CoV-2 uses to infect humans and cause COVID-19. Several studies demonstrated that the non-human primate (NHP) is permissive for SARS-CoV-2 infection to cause typical clinical symptoms including fever, cough, breathing difficulty, and other diagnostic abnormalities such as immunopath
    Document: SARS-CoV-2 has been the causative pathogen of the pandemic of COVID-19, resulting in catastrophic health issues globally. It is important to develop human-like animal models for investigating the mechanisms that SARS-CoV-2 uses to infect humans and cause COVID-19. Several studies demonstrated that the non-human primate (NHP) is permissive for SARS-CoV-2 infection to cause typical clinical symptoms including fever, cough, breathing difficulty, and other diagnostic abnormalities such as immunopathogenesis and hyperplastic lesions in the lung. These NHP models have been used for investigating the potential infection route and host immune response to SARS-CoV-2, as well as testing vaccines and drugs. This review aims to summarize the benefits and caveats of NHP models currently available for SARS-CoV-2, and to discuss key topics including model optimization, extended application, and clinical translation.

    Search related documents:
    Co phrase search for related documents
    • acute sars cov respiratory syndrome coronavirus and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and ade evaluate: 1
    • acute sars cov respiratory syndrome coronavirus and local infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung lesion: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and lung pathogenesis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immunity and local infection: 1, 2
    • adaptive immunity and lung injury: 1, 2, 3, 4, 5, 6, 7
    • adaptive immunity and lung pathogenesis: 1, 2, 3
    • local infection and lung injury: 1
    • local infection and lung pathogenesis: 1